Lyra Therapeutics (LYRA) Net Margin (2021 - 2025)
Lyra Therapeutics (LYRA) has disclosed Net Margin for 5 consecutive years, with 23936.0% as the latest value for Q3 2025.
- On a quarterly basis, Net Margin fell 1784728.0% to 23936.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 3527.52%, a 1016327.0% increase, with the full-year FY2023 number at 4023.11%, up 3251.0% from a year prior.
- Net Margin was 23936.0% for Q3 2025 at Lyra Therapeutics, down from 4063.93% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 828.6% in Q4 2024 to a low of 129290.91% in Q4 2022.
- A 5-year average of 17265.09% and a median of 4220.3% in 2024 define the central range for Net Margin.
- Peak YoY movement for Net Margin: crashed -12426619bps in 2022, then skyrocketed 11891009bps in 2023.
- Lyra Therapeutics' Net Margin stood at 5024.72% in 2021, then tumbled by -2473bps to 129290.91% in 2022, then soared by 92bps to 10380.82% in 2023, then surged by 108bps to 828.6% in 2024, then tumbled by -2989bps to 23936.0% in 2025.
- Per Business Quant, the three most recent readings for LYRA's Net Margin are 23936.0% (Q3 2025), 4063.93% (Q2 2025), and 4670.49% (Q1 2025).